logo
Why do sharks freeze when flipped upside down?

Why do sharks freeze when flipped upside down?

Yahoo19-07-2025
When you buy through links on our articles, Future and its syndication partners may earn a commission.
Sharks can be formidable predators, but when they're flipped upside down, many species enter a trance-like state, known as tonic immobility, and are as helpless as a beetle on its back.
Tonic immobility is "as close to hypnotising a shark as you can get!" Joel Gayford, a doctoral candidate of marine ecology at James Cook University in Australia, told Live Science in an email. "The animal completely stops swimming, and the only movement it's making is slow rhythmic breathing."
But what happens when a shark enters this state? And why do sharks freeze when turned belly-up?
During tonic immobility, a shark experiences a decrease in sensory responsiveness, cardiac rate and blood pressure, as well as analgesia, meaning a decrease in its sensitivity to pain, Abraham Miranda-Páez, a researcher at the Mexican nonprofit Pelagios Kakunjá that aims to conserve sharks and manta rays, told Live Science in an email.
Sign up for our newsletter
Sign up for our weekly Life's Little Mysteries newsletter to get the latest mysteries before they appear online.
For the shark species that go into tonic immobility — including great white sharks (Carcharodon carcharias), lemon sharks (Negaprion brevirostris) and gray nurse sharks (also known as a sand tiger shark, or Carcharias taurus) — this freeze response "can be induced when the shark is flipped over or by stimulating the snout (home to lots of electroreceptors called the ampullae of Lorenzini), Jillian Morris, founder of Sharks4Kids, a Florida-based nonprofit, told Live Science in an email.
By putting sharks into this snoozing state, scientists can conduct research safely while reducing stress for the animal.
"We can make a small incision and insert an acoustic tag safely and humanely, without the need for special equipment," Morris said. "It's always done very quickly, and then the shark is flipped back over."
Related: Can turtles really breathe through their butts?
How tonic immobility helps sharks survive
But sharks didn't evolve this trait to help scientists take samples, so what's going on?
There are a few leading theories. According to a 2023 study in the journal Environmental Biology of Fishes, tonic immobility could be for self-defense, courtship or protection from sensory overload. "The consensus among the scientific community is that tonic immobility is a passive defensive response," said Miranda-Páez, co-author of the study.
In other species, playing dead can be helpful. Dice snakes and fire ants pretend they've popped their clogs when predators attack, while female dragonflies and European common frogs fake their own death to avoid sex.
But not everyone is convinced that paralysis would be effective protection for sharks. "This explanation doesn't work very well for sharks," Gayford said. "Most shark predators would not be deterred by a motionless target."
In some instances, it's a clear disadvantage — orcas have worked out that they can incapacitate sharks to overpower them and gobble down their nutrient-rich livers.
Sharks go into this state during sex, said Morris, who has observed nurse sharks mating. "The male flips the female over, and she enters tonic immobility before copulation." However, males are affected too, "so mating does not fully explain why this phenomenon occurs," she added.
A 2025 study in the journal Reviews in Fish Biology and Fisheries suggests that tonic immobility has no purpose and is just an evolutionary hangover. "We actually found that tonic immobility has been lost independently several times throughout the evolutionary history of sharks and rays," said Gayford, a co-author of the study.
RELATED MYSTERIES
—Which animals can hold their breath underwater the longest?
—What is the oldest shark?
—What's the biggest freshwater fish in the world?
Many of the species that don't have this response probably lost it for a reason, Gayford said. Typically, small coral-dwelling sharks spend lots of time looking for food in tight spots, where they could get stuck. "If these species were to go into tonic in this situation, it could have deadly consequences," Gayford said.
For now, scientists don't have enough data to conclusively say what purpose tonic immobility serves. "There are many theories, none of which are fully understood or thoroughly supported," Morris said.
Shark quiz: How much do you know about these iconic ocean superstars?
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Immutep Announces Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025
Immutep Announces Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025

Yahoo

time16 hours ago

  • Yahoo

Immutep Announces Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025

SYDNEY, AUSTRALIA, July 28, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ('Immutep' or 'the Company'), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces three abstracts for clinical trials evaluating its first-in-class MHC Class II agonist, eftilagimod alfa (efti), have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2025 taking place 17-21 October in Berlin, Germany. A Proffered Paper oral presentation will detail results from EFTISARC-NEO, a Phase II investigator-initiated trial in resectable soft tissue sarcoma, and data from the INSIGHT-003 Phase I investigator-initiated trial in first-line non-small cell lung cancer (1L NSCLC) has been accepted for poster presentation. Additionally, an abstract on the Company's pivotal TACTI-004 Phase III in 1L NSCLC has been accepted for a Trials in Progress ePoster. Details of the presentations are as follows: Title: EFTISARC-NEO: A phase II study of neoadjuvant eftilagimod alpha, pembrolizumab and radiotherapy in patients with resectable soft tissue sarcoma Presenter: Katarzyna Kozak, M.D., Ph.D., Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland Session Category: Proffered Paper Session Title: Sarcoma Presentation #: 2686O Date and Time: Sunday, 19 October 2025 at 16:30 – 18:00 PM CET Title: Eftilagimod alpha (soluble LAG-3 protein) combined with 1st line chemo-immunotherapy in metastatic non-squamous non-small cell lung cancer (NSCLC) –Updates from INSIGHT-003 (IKF614) Presenter: Dr. med. Akin Atmaca, Department of Hematology and Oncology, Krankenhaus Nordwest, UCT-University Cancer Center, Frankfurt, Germany Session Category: Poster Session Title: NSCLC, metastatic Presentation #: 1857P Date and Time: Saturday, 18 October 2025 at 12:00 – 12:45 PM CET Title: TACTI-004, a double-blinded, randomised phase 3 trial of eftilagimod alfa plus pembrolizumab (P) + chemotherapy (C) vs placebo + P + C in 1st line advanced/metastatic NSCLC Presenter: Prof. Dr. med. Hans-Georg Kopp, Robert Bosch Hospital, Stuttgart, Germany Session Category: ePoster Session Title: NSCLC, metastatic Presentation #: 2086eTiP Proffered Papers at ESMO are oral presentations of original data of superior quality, followed by expert discussion and perspectives. Abstracts will be made available on the ESMO website on 13 October 2025 at 00.05 CET. The posters will be available on the Posters & Publications section of Immutep's website after their presentations. About ImmutepImmutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3's ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit Australian Investors/Media:Eleanor Pearson, Sodali & Co.+61 2 9066 4071; U.S. Media:Chris Basta, VP, Investor Relations and Corporate Communications+1 (631) 318 4000;

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)
Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Yahoo

time16 hours ago

  • Yahoo

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Lu177-B7H3 monoclonal antibody is first in class targeted radiopharmaceutical in development against the 4lg subtype of B7-H3 On track to initiate first-in-human study of RV-01 in solid tumors in 4Q25 SYDNEY, July 28, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, 'Radiopharm' or the 'Company'), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) has provided clearance of the Company's Investigational New Drug (IND) application for Betabart (RV-01), its Lu177-B7H3 monoclonal antibody designed with strong affinity for the 4Ig isoform of B7H3 that is highly expressed in tumors and not in healthy tissues. 'FDA clearance to initiate our first-in-human Phase 1 clinical trial of RV-01 represents a major milestone for Radiopharm Theranostics and our joint venture with MD Anderson Cancer Center,' said Riccardo Canevari, CEO and Managing Director. 'RV-01 is the first monoclonal antibody developed through this collaboration, and we believe it has the potential to become a highly differentiated radiopharmaceutical for patients with aggressive solid tumors. We are excited to advance this program into the clinic and anticipate dosing the first patients later this year.' 'Recent reported preclinical studies demonstrated that RV-01 exhibits hepatic clearance, allowing the isotope sufficient time to effectively target tumors while potentially minimizing adverse effects such as hematological toxicities. Unlike peptides or small molecules, monoclonal antibodies are primarily cleared by the liver—an organ known for its radio-resistance. This characteristic, combined with the shortened half-life of RV-01 and the strong affinity for the target make this agent stand out and may offer a significant advantage not just over other monoclonal antibodies but also targeted radiotherapeutics with renal excretion pathway, the latter of which are often associated with higher risk of radiopharmaceutical-induced kidney toxicity,' noted Dimitris Voliotis, M.D., Chief Medical Officer of Radiopharm Theranostics. 'The high affinity and selectivity of RV-01 for the 4Ig isoform of B7H3 allows the antibody to bypass the soluble 2Ig isoform in the blood, boost binding of the radiopharmaceutical to tumor targets and avoid the formation of immune complexes in circulation,' noted David Piwnica-Worms, M.D., Ph.D., Professor, MD Anderson Cancer Center, and scientific co-founder of Radiopharm Ventures. B7-H3 is an immune checkpoint molecule that is overexpressed across several tumor types and has emerged as a compelling target for antibody-based cancer immunotherapy. Deregulated B7-H3 expression is consistently correlated with enhanced tumor aggressiveness and poor clinical outcomes. Targeting the 4 Ig isoform of B7-H3 with a selective radioligand therapy may offer a novel strategy for treating refractory or high-risk tumors. About RV-01 RV-01 is the first radiopharmaceutical therapeutic agent developed by Radiopharm Ventures, the Joint Venture formed between Radiopharm Theranostics and MD Anderson Cancer Center (MDACC). RV-01 is a 177Lutetium-conjugated therapeutic that targets B7-H3, an immune checkpoint molecule that is overexpressed in several tumor types. Multiple preclinical studies with RV-01 have shown tumor shrinkage and prolonged survival in animals treated with the radiotherapeutic agent. RV-01 has received IND-clearance from the U.S. FDA and plans to initiate a first-In-human Phase 1 study in the second half of 2025. About Radiopharm Theranostics Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and three Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain. Learn more at Authorized on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman Paul Hopper. For more information: Investors:Riccardo CanevariCEO & Managing DirectorP: +1 862 309 0293E: rc@ Anne Marie FieldsPrecision AQ (formerly Stern IR)E: Media:Matt WrightNWR CommunicationsP: +61 451 896 420E: matt@ Follow Radiopharm Theranostics: Website – X – – –

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store